#37 - Colin Weller, VP & GM Evidence Platform at Medable
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Join us on the latest episode! Our Guest: Colin Weller, VP & GM of Evidence Platform at Medable.
What you'll get out of this episode:
- Introduction of Colin Weller: Vice President and GM of Evidence Platform at Medable, Colin Weller discusses his role in advancing clinical research technology to streamline drug approvals.
- Challenges in Drug Development: Weller details the stagnant pace of drug development, highlighting the industry's need for innovation to improve efficiency and reduce costs.
- Medable's Ambitious Goals: Aiming to increase the number of drugs approved annually by tenfold through advanced SAS technology and AI, setting a new industry standard.
- Innovations in Clinical Trials: Medable has already cut study startup times by 50%, utilizing AI and automation to overhaul traditional processes.
- Future of Digital Clinical Trials: Weller predicts significant advancements in decentralized and digital trials, enhancing patient accessibility and data quality.
To learn more about our guests and their companies:
LinkedIn: https://www.linkedin.com/in/colin-weller-294ab58/
Company LinkedIn: https://www.linkedin.com/company/medable-inc-/
Website: https://www.medable.com/
Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/
BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/